 |
85 Diseases |  |
38 Trials |
|
38 Trials |  |
1659 News |  |
| 12345678910111213...1314» |
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
New trial: A Trial of Three- and Seven-days Insulin Infusions Set (clinicaltrials.gov) - Aug 1, 2024
P=N/A, N=80, Recruiting, Sponsor: Steno Diabetes Center Copenhagen
- NovoLog (insulin aspart) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
TREATING DIABETIC KETOACIDOSIS IN A PATIENT ALLERGIC TO REGULAR INSULIN (Convention Center 256) - Jul 31, 2024 - Abstract #CHEST2024CHEST_4928;
Allergy to the insulin molecule is rare and poses challenges to treatment in the critical care unit. Using a less immunogenic formulation and/or a rapid desensitization protocol may be lifesaving in patients.
- Clotinab (abciximab) / ISU Abxis, Integrilin (eptifibatide) / Takeda, NovoLog (insulin aspart) / Novo Nordisk
Keeping Coronary Stents Patent in Patients (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3263;
(ASA, Clopidogrel (Plavix), Eptifibatide (Integrelin), Abciximab (Reopro), prasugrel (Effient), ticagrelor (Brilinta) Intra operatively, the patient develops hypotension, ST elevation and T wave inversion on EKG.16. What are the therapeutic options available in this scenario?
- Clotinab (abciximab) / ISU Abxis, Integrilin (eptifibatide) / Takeda, NovoLog (insulin aspart) / Novo Nordisk
Keeping Coronary Stents Patent in Patients (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_481;
(ASA, Clopidogrel (Plavix), Eptifibatide (Integrelin), Abciximab (Reopro), prasugrel (Effient), ticagrelor (Brilinta) Intra operatively, the patient develops hypotension, ST elevation and T wave inversion on EKG.16. What are the therapeutic options available in this scenario?
- | NovoLog (insulin aspart) / Novo Nordisk
Journal: Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid (Pubmed Central) - Jun 1, 2024
What are the therapeutic options available in this scenario? The correlation studies also showed absence of association between AIA antibody levels and percentage glucose uptake in both BGL-ASP and RMP-NovoRapid
- What will be the impact on minority groups in 2026 when Medicare Part D price cuts take effect? () - Apr 9, 2024 - Abstract #AMCP2024AMCP_188;
All 3 groups have higher use than Medicare enrollees overall, for use of selected diabetes drugs, Farxiga (dapagliflozin), Januvia (sitagliptin), and Jardiance (empagliflozin). Black and Latino enrollees also index higher for use of Novolog/Fiasp (insu- lin aspart)...Latino people
- | NovoLog (insulin aspart) / Novo Nordisk
Journal, Surgery: Enhanced recovery after surgery: Preoperative carbohydrate loading and insulin management in type 2 diabetes. (Pubmed Central) - Mar 11, 2024
Black and Latino enrollees also index higher for use of Novolog/Fiasp (insu- lin aspart)...Latino people Patients enrolled in an ERAS
- ||||| Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment closed, Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Mar 5, 2024
P3, N=319, Active, not recruiting, Sponsor: Mannkind Corporation
Patients enrolled in an ERAS Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024
- | SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi
Journal: Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial. (Pubmed Central) - Feb 29, 2024
SAR341402 insulin aspart (SAR-Asp) is a rapid-acting insulin analog developed as an interchangeable biosimilar to the marketed insulin aspart reference product (NovoLog; NN-Asp)...This report assessed whether multiple switches between SAR-Asp and NN-Asp lead to equivalent safety and efficacy compared with continuous use of NN-Asp in adults with type 1 diabetes (T1D) treated with multiple daily injections, using once-daily insulin glargine U100 (Lantus) as the basal insulin...Alternating doses of SAR-Asp and NN-Asp compared with continuous use of NN-Asp showed similar safety, immunogenicity, and clinical efficacy in adults with T1D. This study supports interchangeability between SAR-Asp and NN-Asp in T1D management.
- ||| HR011408 (rapid-acting insulin biosimilar) / Jiangsu Hengrui Pharma
Trial completion: The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid (clinicaltrials.gov) - Feb 7, 2024
P1, N=61, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This study supports interchangeability between SAR-Asp and NN-Asp in T1D management. Recruiting --> Completed
- || SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
PK/PD data, Journal: Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. (Pubmed Central) - Jan 9, 2024
Recruiting --> Completed PK exposure of SAR-Asp (switching group) and reference NN-Asp (non-switching group) were similar, supporting interchangeability between these two insulin aspart products.
- ||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Jan 5, 2024
P3, N=264, Recruiting, Sponsor: Mannkind Corporation
PK exposure of SAR-Asp (switching group) and reference NN-Asp (non-switching group) were similar, supporting interchangeability between these two insulin aspart products. Trial completion date: Apr 2024 --> Apr 2025
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Dec 28, 2023
P4, N=60, Completed, Sponsor: The Cleveland Clinic
Trial completion date: Apr 2024 --> Apr 2025 Active, not recruiting --> Completed
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Dec 26, 2023
P3, N=139, Completed, Sponsor: Boston Medical Center
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
- ||||||| NovoLog (insulin aspart) / Novo Nordisk
Trial completion: A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety (clinicaltrials.gov) - Dec 22, 2023
P3, N=563, Completed, Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
Recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023 Unknown status --> Completed
- | Trial completion date: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Dec 15, 2023
P=N/A, N=150, Active, not recruiting, Sponsor: Weill Cornell Medical College in Qatar
Unknown status --> Completed Trial completion date: Oct 2023 --> Oct 2024
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Trial completion, Trial completion date, Trial primary completion date: Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal (clinicaltrials.gov) - Nov 30, 2023
P4, N=72, Completed, Sponsor: Medical University of Warsaw
Trial completion date: Oct 2023 --> Oct 2024 Recruiting --> Completed | Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jul 2022 --> Jan 2023
- |||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Sep 13, 2023
P3, N=264, Recruiting, Sponsor: Mannkind Corporation
Recruiting --> Completed | Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jul 2022 --> Jan 2023 Trial primary completion date: Aug 2023 --> Dec 2023
- Clotinab (abciximab) / ISU Abxis, Integrilin (eptifibatide) / Takeda, NovoLog (insulin aspart) / Novo Nordisk
Keeping Coronary Stents Patent In Patients (South: Hall D-7) - Jul 20, 2023 - Abstract #ASA2023ASA_356;
His past medical history was significant for coronary artery disease, myocardial infarction 10 years ago followed by a coronary artery bypass surgery, ESRD on dialysis three times a week via an arterio-venous fistula, diabetes mellitus, obstructive sleep apnea and a history of deep vein thrombosis (was on warfarin until 2 years ago).Medications: Novolog, glipizide, metoprolol, carvedilol, lisinopril, lasix, aspirin (ASA), nitroglycerin (NTG) patch.Dialyzed: 1 day agoECG- inferolateral ischemiaMeds taken: metoprolol, carvedilol, NTG patch.Recent stress test at outside hospital (copy requested)Cardiac catheterization...What is the implication of Dabigatran (Pradaxa) as compared to clopidogrel (Plavix) or ASA?10...(ASA, Clopidogrel (Plavix), Eptifibatide (Integrelin), Abciximab (Reopro)Intra operatively, the patient develops hypotension, ST elevation and T wave inversion on EKG.16. What are the therapeutic options available in this scenario?
- ||||| I004 (insulin aspart rapid-acting biosimilar) / Amphastar
Trial completion, Trial completion date: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (clinicaltrials.gov) - Jul 20, 2023
P2/3, N=69, Completed, Sponsor: Amphastar Pharmaceuticals, Inc.
What are the therapeutic options available in this scenario? Recruiting --> Completed | Trial completion date: May 2023 --> Jan 2023
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Enrollment change, Trial completion date: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Jul 7, 2023
P4, N=60, Active, not recruiting, Sponsor: The Cleveland Clinic
Recruiting --> Completed | Trial completion date: May 2023 --> Jan 2023 Recruiting --> Active, not recruiting | N=100 --> 60 | Trial completion date: Jun 2023 --> Nov 2023
- NovoLog (insulin aspart) / Novo Nordisk
Effect of intra-nasal insulin therapy on food intake among African American adults: the FIINAAL study (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1666;
Recruiting --> Active, not recruiting | N=100 --> 60 | Trial completion date: Jun 2023 --> Nov 2023 This double-blind, placebo-controlled, randomized crossover study compared a single intranasal dose of 10 IUs of Novolog
- | NovoLog (insulin aspart) / Novo Nordisk
Preclinical, Journal: In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart. (Pubmed Central) - Jun 7, 2023
This double-blind, placebo-controlled, randomized crossover study compared a single intranasal dose of 10 IUs of Novolog The biological characterization studies of BGL-ASP demonstrated high binding and functional similarity to NovoRapid.
- | NovoLog (insulin aspart) / Novo Nordisk
Consultant joked about slow novorapid! (Twitter) - Jun 3, 2023
- Keytruda (pembrolizumab) / Merck (MSD), Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Late Onset of Immune Checkpoint Inhibitor-related Diabetes after 3 years (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_181;
He had recent evidence of progression, so chemotherapy adjustment was planned, and he started dexamethasone 4mg on the day prior to presentation...He continued to have hyperglycaemia while on NPH /Novolog regimen, thus he was switched to Lantus and Novolog regimen with better glycaemic control... Although the mean interval between the first ICI administration and T1DM development was found to be 201
- |||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - May 8, 2023
P3, N=264, Recruiting, Sponsor: Mannkind Corporation
Although the mean interval between the first ICI administration and T1DM development was found to be 201 Trial primary completion date: Apr 2023 --> Aug 2023
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes (clinicaltrials.gov) - May 6, 2023
P3, N=216, Completed, Sponsor: Rigshospitalet, Denmark
Trial primary completion date: Apr 2023 --> Aug 2023 Active, not recruiting --> Completed
- | NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial termination: Carbohydrate Consumption as a Factor in Aspart Dosing (clinicaltrials.gov) - May 1, 2023
P4, N=14, Terminated, Sponsor: Rush University Medical Center
Active, not recruiting --> Completed N=30 --> 14 | Completed --> Terminated
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
There is published research comparing novorapid to fiasp in adults - https://t.co/TmGiaIwDgM (Twitter) - Apr 27, 2023
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 25, 2023
P3, N=160, Recruiting, Sponsor: Boston Medical Center
N=30 --> 14 | Completed --> Terminated Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023
- || HR011408 (rapid-acting insulin biosimilar) / Jiangsu Hengrui Pharma
Enrollment open: The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid (clinicaltrials.gov) - Apr 12, 2023
P1, N=44, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk, ultra-rapid acting insulin (AT247) / Arecor, NovoLog (insulin aspart) / Novo Nordisk
Double-Blind Crossover Study of Ultra-Rapid AT247 Compared with NovoLog and Fiasp during Continuous Subcutaneous Infusion (CSII) Assessed by a Hyperinsulinemic Euglycemic Clamp (Poster Halls B-C; [Board No. 805]) - Apr 10, 2023 - Abstract #ADA2023ADA_488;
The faster absorption of AT247 resulted in higher early insulin exposure than for F or N following bolus dose delivery during CSII. The demonstrated PK profile of AT247 supports further investigation into its potential to further improve automated insulin delivery.
- | SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Preclinical, Journal: In vitro stability of biosimilar insulin aspart SAR341402 in the Medtronic MiniMed insulin pumps: Running title: Similarity of insulin aspart products in simulated CSII (48 characters). (Pubmed Central) - Mar 21, 2023
Leachable profiles from pump and reservoir samples were similar in all product batches. Like NovoLog
- || NovoLog (insulin aspart) / Novo Nordisk
It's been taken off the PBS, so we'll have to pay for a private script (~$250 cf $30). There's no equivalent in Australia. Closest insulin is novorapid, but the onset time differs by about 30mins. It means prebolusing, which is a step backwards. (Twitter) - Mar 16, 2023
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
As far as I can tell, fiasp = novorapid with more preservatives in it (would explain the added site failures), to prolong shelf life and increase profits. (Twitter) - Mar 11, 2023
- || ultra-rapid-acting concentrated insulin aspart (AT278) / Arecor
New P1 trial: AT278, NovoRapid (clinicaltrials.gov) - Mar 3, 2023
P1, N=32, Recruiting, Sponsor: Arecor Limited
- || HR011408 (rapid-acting insulin biosimilar) / Jiangsu Hengrui Pharma
New P1 trial: The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid (clinicaltrials.gov) - Feb 21, 2023
P1, N=44, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| HR20014 / Jiangsu Hengrui Pharma, INS062 / Jiangsu Hengrui Pharma
New P1 trial: Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects (clinicaltrials.gov) - Feb 9, 2023
P1, N=60, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | NovoLog (insulin aspart) / Novo Nordisk
That’s expensive, but it’s ~$22 per unit, not ~100 per unit. If he can get switched to Novolog pens, the manufacturer, @novonordiskus, offers coupons. (Twitter) - Feb 7, 2023
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
@novonordisk, misschien niet tegen de specialisten zeggen dat ozempic terug vlot te krijgen is? Ozempic 1mg is nog steeds moeilijk te verkrijgen via jullie. Wees correct in jullie communicatie net zoals eind vorig jaar met novorapid. Stel jullie niet beter voor dan jullie zijn. (Twitter) - Feb 3, 2023
- || Tresiba (insulin degludec) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Pharmacies should be allowed to dispense single insulin pens to diabetics instead of the full box across the counter #diabetes #insulin #novorapid #tresiba @novonordisk @teamnovonordisk (Twitter) - Dec 24, 2022
- ||| NovoLog (insulin aspart) / Novo Nordisk
I ran @maratonmalaga (half) in the @TDFCdiabetes vest on Sunday as a training session. Went well and the glucose levels behaved very well for the 81 minutes they needed too! The eagle eyed may be able to spot a @novonordisk NovoRapid FlexPen in the main pic too! #GBDoc #ukrunchat (Twitter) - Dec 14, 2022
- | HinsBet (human insulin) / Adocia, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial termination: Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas (clinicaltrials.gov) - Dec 9, 2022
P2/3, N=20, Terminated, Sponsor: Massachusetts General Hospital
Like NovoLog N=45 --> 20 | Enrolling by invitation --> Terminated; Devices are not available
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Journal: Influence of insulin collection preservatives in postmortem blood: application to a case of insulin aspart suicide. (Pubmed Central) - Dec 7, 2022
During a degradation study implemented to compare 3 preservatives and dry tubes, suitable insulin aspart stability was observed with EDTA and NaF. Given NaF is standard in forensic toxicology for measuring blood alcohol concentrations, the authors suggest its use for blood collection when insulin intoxication is suspected.
- || NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial. (Pubmed Central) - Nov 22, 2022
Comparable improvements were reported for mean 2-hour PPG (6.14 and 6.29 mmol/L), FPG (2.02 and 1.70 mmol/L), and patients with HbA1c <7.0% (52.6% and 51.0%) and ≤6.5% (34.2% and 30.9%), in the Rapilin and NovoRapid groups, respectively, with no significant safety or immunogenicity outcome differences. Rapilin demonstrated noninferior glycemic control, and matching safety and immunogenicity to NovoRapid in patients with type 2 diabetes mellitus also receiving metformin over 24 weeks.
- | Kixelle (insulin aspart biosimilar) / Viatris, Biocon, NovoLog (insulin aspart) / Novo Nordisk
Journal: Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study. (Pubmed Central) - Nov 15, 2022
P3
MYL-1601D demonstrated similar immunogenicity, efficacy, and safety profiles to Ref-InsAsp-US in patients with T1D over 24 weeks. CLINICAL TRIAL REGISTRATION CLINICALTRIALS.GOV: NCT03760068.
- Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Faster-acting insulin Fiasp vs insulin Novorapid in type 1 diabetes children and adolescents with sensor-augmented pump therapy (Rome, Italy) - Nov 13, 2022 - Abstract #ESPE2022ESPE_686;
Most of the participants were receiving Novorapid before the initiation of the study (51.5%), while 3 out of 10 (30.3%) were receiving lispro (Humalog). Fiasp and NovoRapid are equally efficient in children and adolescents with TIDM treated with SAP with no difference in glycemic control.
- || NovoLog (insulin aspart) / Novo Nordisk
And @NovoNordisk takes the prize, with a WAC of $558.83 for its Novolog product. (Twitter) - Nov 12, 2022
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Trial primary completion date: Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes (clinicaltrials.gov) - Oct 26, 2022
P3, N=216, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Fiasp and NovoRapid are equally efficient in children and adolescents with TIDM treated with SAP with no difference in glycemic control. Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Mar 2023
- |||||||| I004 (insulin aspart rapid-acting biosimilar) / Amphastar
New P2/3 trial: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (clinicaltrials.gov) - Sep 14, 2022
P2/3, N=60, Recruiting, Sponsor: Amphastar Pharmaceuticals, Inc.